Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-07-28 03:19Group 1 - The innovative drug sector in Hong Kong and A-shares continues to strengthen, with notable gains in stocks such as MicroPort Medical, China Biologic Products, and Innovent Biologics [1] - On July 28, 2025, Hengrui Medicine announced an agreement with GSK, granting GSK exclusive global rights to the HRS-9821 project and up to 11 other projects, with an upfront payment of $500 million and potential milestone payments totaling approximately $12 billion [1] - Haitong International highlights the sustained high prosperity in the innovative drug sector, with Pharma companies expected to undergo a revaluation, while Biopharma/Biotech companies show strong growth potential as their innovative pipelines begin to yield results [1] Group 2 - The Hang Seng Biotechnology ETF (159615) closely tracks the Hang Seng Biotechnology Index, which reflects the overall performance of the largest 50 biotechnology companies listed in Hong Kong [2] - The top ten weighted stocks in the Hang Seng Biotechnology Index include Innovent Biologics, WuXi Biologics, BeiGene, and others [2] - The Southern Innovative Drug ETF (159858) tracks the CSI Innovative Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development [2]